Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Companies added to the blacklist can be subject to fines and other sanctions, including a freeze on trade and a revocation of ...

PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Leerink Partn ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...